Publication Date:
2011-03-11
Description:
B-cell non-Hodgkin's lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting oncogenes and tumour-suppressor genes. We report here that the two most common types--follicular lymphoma and diffuse large B-cell lymphoma--harbour frequent structural alterations inactivating CREBBP and, more rarely, EP300, two highly related histone and non-histone acetyltransferases (HATs) that act as transcriptional co-activators in multiple signalling pathways. Overall, about 39% of diffuse large B-cell lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or somatic mutations that remove or inactivate the HAT coding domain of these two genes. These lesions usually affect one allele, suggesting that reduction in HAT dosage is important for lymphomagenesis. We demonstrate specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 tumour suppressor. These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin's lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271441/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271441/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Pasqualucci, Laura -- Dominguez-Sola, David -- Chiarenza, Annalisa -- Fabbri, Giulia -- Grunn, Adina -- Trifonov, Vladimir -- Kasper, Lawryn H -- Lerach, Stephanie -- Tang, Hongyan -- Ma, Jing -- Rossi, Davide -- Chadburn, Amy -- Murty, Vundavalli V -- Mullighan, Charles G -- Gaidano, Gianluca -- Rabadan, Raul -- Brindle, Paul K -- Dalla-Favera, Riccardo -- 1R01LM010140-01/LM/NLM NIH HHS/ -- DE018183/DE/NIDCR NIH HHS/ -- P01 CA092625/CA/NCI NIH HHS/ -- P01 CA092625-05/CA/NCI NIH HHS/ -- P01-CA092625/CA/NCI NIH HHS/ -- P30 CA021765/CA/NCI NIH HHS/ -- R01-CA37295/CA/NCI NIH HHS/ -- R37 CA037295/CA/NCI NIH HHS/ -- R37 CA037295-28/CA/NCI NIH HHS/ -- U54-AI057158/AI/NIAID NIH HHS/ -- England -- Nature. 2011 Mar 10;471(7337):189-95. doi: 10.1038/nature09730.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA. lp171@columbia.edu〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21390126" target="_blank"〉PubMed〈/a〉
Keywords:
Acetyl Coenzyme A/metabolism
;
Acetylation
;
Acetyltransferases/chemistry/deficiency/*genetics/*metabolism
;
Animals
;
Base Sequence
;
CREB-Binding Protein/chemistry/deficiency/*genetics/metabolism
;
Cells, Cultured
;
DNA-Binding Proteins/metabolism
;
E1A-Associated p300 Protein/chemistry/deficiency/*genetics/metabolism
;
Gene Expression Regulation, Neoplastic
;
HEK293 Cells
;
Histone Acetyltransferases/chemistry/deficiency/genetics/metabolism
;
Humans
;
Lymphoma, B-Cell/*enzymology/*genetics/pathology
;
Lymphoma, Follicular/enzymology/genetics/pathology
;
Lymphoma, Large B-Cell, Diffuse/enzymology/genetics/pathology
;
Mice
;
Mutation/*genetics
;
Mutation, Missense/genetics
;
Polymorphism, Single Nucleotide/genetics
;
Protein Binding
;
Protein Structure, Tertiary/genetics
;
Recurrence
;
Sequence Deletion/genetics
;
Tumor Suppressor Protein p53/metabolism
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
